论文部分内容阅读
重点介绍进入临床研究阶段的4个新抗癫痫药。氟桂利嗪为选择性钙通道拮抗剂，是一种长效抗惊厥药，对复杂性部分性癫痫发作的效果与苯妥美和卡马西平类似；磷苯妥美在体内迅速转变为苯妥英，注射剂型轻苯妥英的水溶性好，且无静注刺激症状；咪达唑仑为水溶性苯二氮类药物，其镇静、肌松、对脑电描记测量的影响均强于地西泮（安定），对顽固性癫痫持续状态有效；司替戊醇有抗惊厥和抑制细胞色素P450的作用，故明显影响其它机惊厥药物的代谢。该药已在患局部性癫痫、顽固性癫痫和顽固性无惊厥的癫痫病人上显示一些疗效。
Highlights four new antiepileptic drugs entering the clinical research phase. Flunarizine is a selective calcium channel antagonist, is a long-acting anticonvulsant, the effect of complex partial seizures and phenytoin and carbamazepine similar; phosphorus phenytoin in the body quickly converted to phenytoin, Injection of phenytoin good water-soluble, and no intravenous irritation; midazolam is a water-soluble benzodiazepine drugs, the sedation, muscle relaxation, the impact of electroencephalographic measurements were stronger than diazepam ), Persistent status of intractable epilepsy; Secretary for pentyl alcohol anticonvulsant and inhibit the role of cytochrome P450, it significantly affect the metabolism of other anticonvulsant drugs. This medicine has shown some efficacy in patients with epilepsy, intractable epilepsy, and refractory epilepsy without convulsion.